Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study
In a retrospective cohort study, Simon Cauchemez and colleagues find viral load can predict case fatality ratios among patients with Ebola Virus.
Vyšlo v časopise:
Use of Viremia to Evaluate the Baseline Case Fatality Ratio of Ebola Virus Disease and Inform Treatment Studies: A Retrospective Cohort Study. PLoS Med 12(12): e32767. doi:10.1371/journal.pmed.1001908
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001908
Souhrn
In a retrospective cohort study, Simon Cauchemez and colleagues find viral load can predict case fatality ratios among patients with Ebola Virus.
Zdroje
1. WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481–1495. doi: 10.1056/NEJMoa1411100 25244186
2. World Health Organization. Ebola situation report. 23 September 2015. Available: http://apps.who.int/iris/bitstream/10665/185279/1/ebolasitrep_23Sept2015_eng.pdf?ua=1. Accessed 28 September 2015.
3. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53. doi: 10.1038/nature13777 25171469
4. Sissoko D, Anglaret X, Malvy D, Folkesson E, Abdoul M, Shepherd S, et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea [abstract]. Conference on Retroviruses and Opportunistic Infections 2015; 23–26 Feb 2015; Seattle, Washington, US. Available: http://www.croiconference.org/sessions/favipiravir-patients-ebola-virus-disease-early-results-jiki-trial-guinea. Accessed 12 May 2015.
5. Hampton T. Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight. JAMA. 2014;312:987–989. doi: 10.1001/jama.2014.11170 25162140
6. Cox E, Borio L, Temple R. Evaluating Ebola therapies—the case for RCTs. N Engl J Med. 2014;371:2350–2351. doi: 10.1056/NEJMp1414145 25470568
7. Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014;312:1299–1300. doi: 10.1001/jama.2014.12867 25211645
8. Joffe S. Ethical testing of experimental Ebola treatments—reply. JAMA. 2014;313:422. doi: 10.1001/jama.2014.17262
9. Shaw D. Randomisation is essential in Ebola drug trials. Lancet. 2014;384:1667. doi: 10.1016/S0140-6736(14)61735-9 25441188
10. Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy JF, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384:1423–1424. doi: 10.1016/S0140-6736(14)61734-7 25390318
11. Folayan MO, Haire B, Peterson K. Ethical testing of experimental Ebola treatments. JAMA. 2014;313:421.
12. WHO Ebola Response Team, Agua-Agum J, Ariyarajah A, Aylward B, Blake IM, Brennan R, et al. West African Ebola epidemic after one year—slowing but not yet under control. N Engl J Med. 2015;372:584–587. doi: 10.1056/NEJMc1414992 25539446
13. Lefebvre A, Fiet C, Belpois-Duchamp C, Tiv M, Astruc K, Aho Glélé LS. Case fatality rates of Ebola virus diseases: a meta-analysis of World Health Organization data. Med Mal Infect. 2014;44:412–416. doi: 10.1016/j.medmal.2014.08.005 25193630
14. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179 (Suppl 1):S177–S187. doi: 10.1086/514321 9988182
15. Weidmann M, Muhlberger E, Hufert FT. Rapid detection protocol for filoviruses. J Clin Virol. 2004;30:94–99. doi: 10.1016/j.jcv.2003.09.004 15072761
16. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–2100. doi: 10.1056/Nejmoa1411680 25353969
17. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330–4341. doi: 10.1128/Jvi.78.8.4330–4341.2004 15047846
18. Bah EI, Lamah MC, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40–47. doi: 10.1056/NEJMoa1411249 25372658
19. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345:1369–1372. doi: 10.1126/science.1259657 25214632
20. Tong Y-G, Shi W-F, Di L, Qian J, Liang L, Bo X-C, et al. Genetic diversity and evolutionary dynamics of Ebola virus in Sierra Leone. Nature. 2015;524:93–96. doi: 10.1038/nature14490 25970247
21. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ. 1978;56:271–293. 307456
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2015 Číslo 12
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Vztah mezi statiny a rizikem vzniku nádorových onemocnění − metaanalýza
- Nech brouka žít… Ať žije astma!
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Self-Administered Outpatient Antimicrobial Infusion by Uninsured Patients Discharged from a Safety-Net Hospital: A Propensity-Score-Balanced Retrospective Cohort Study
- Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials
- Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled
- Police Killings and Police Deaths Are Public Health Data and Can Be Counted